CoChat
Sign Up
Cited by 607Inflammatory Biomarkers in Disease PrognosisSystemic Lupus Erythematosus ResearchRheumatoid Arthritis Research and Therapies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases

Open access
Gasparyan, Armen Yuri, Ayvazyan, Lilit, Mukanova, Ulzhan, Yessirkepov, Marlen, Kitas, George D.·2019·Annals of Laboratory Medicine
DOI 10.3343/alm.2019.39.4.345PMC PMC6400713
Open this paper in CoChat — free accountOpen PDF

Abstract

The platelet-to-lymphocyte ratio (PLR) has emerged as an informative marker revealing shifts in platelet and lymphocyte counts due to acute inflammatory and prothrombotic states. PLR has been extensively examined in neoplastic diseases accompanied by immune suppression and thrombosis, which can be predicted by combined blood cell counts and their ratios. Several large observational studies have demonstrated the value of shifts in PLR in evaluating the severity of systemic inflammation and predicting infections and other comorbidities, in inflammatory rheumatic diseases. The value of PLR as an inflammatory marker increases when its fluctuations are interpreted along with other complementary hematologic indices, particularly the neutrophil-to-lymphocyte ratio (NLR), which provides additional information about the disease activity, presence of neutrophilic inflammation, infectious complications, and severe organ damage in systemic lupus erythematosus. PLR and NLR have high predictive value in rheumatic diseases with predominantly neutrophilic inflammation (e.g., Behçet disease and familial Mediterranean fever). High PLR, along with elevated platelet count, is potentially useful in diagnosing some systemic vasculitides, particularly giant-cell arteritis. A few longitudinal studies on rheumatic diseases have demonstrated a decrease in PLR in response to anti-inflammatory therapies. The main limitations of PLR studies are preanalytical faults, inadequate standardization of laboratory measurements, and inappropriate subject selection. Nonetheless, accumulating evidence suggests that PLR can provide valuable information to clinicians who encounter multisystem manifestations of rheumatic diseases, which are reflected in shifts in platelet, lymphocyte, neutrophil, or monocyte counts. Interpretation of PLR combined with complementary hematologic indices is advisable to more accurately diagnose inflammatory rheumatic diseases and predict related comorbidities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3343/alm.2019.39.4.345

Cites

0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Number of Scopus-indexed articles tagged with the term “platelet lymphocyte ratio” in 2008–2018 (as of October 30, 2018).
Fig. 1 Number of Scopus-indexed articles tagged with the term “platelet lymphocyte ratio” in 2008–2018 (as of October 30, 2018).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 102

  1. [1]Gasparyan AY Stavropoulos-Kalinoglou A Mikhailidis DP Douglas KM Kitas GD Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications Rheumatol Int 2011 31 153 164 20390282
  2. [2]Olumuyiwa-Akeredolu OO Pretorius E Rheumatoid arthritis: notable biomarkers linking to chronic systemic conditions and cancer Curr Pharm Des 2016 22 918 924 26648464
  3. [3]Scherlinger M Guillotin V Truchetet ME Contin-Bordes C Sisirak V Duffau P Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets Autoimmun Rev 2018 17 625 635 29635077
  4. [4]Gasparyan AY Sandoo A Stavropoulos-Kalinoglou A Kitas GD Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy Rheumatol Int 2010 30 1125 1129 20066426
  5. [5]Abdel Galil SM Edrees AM Ajeeb AK Aldoobi GS El-Boshy M Hussain W Prognostic significance of platelet count in SLE patients Platelets 2017 28 203 207 27590999
  6. [6]Lood C Tydén H Gullstrand B Nielsen CT Heegaard NHH Linge P Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus Rheumatology (Oxford) 2017 56 408 416 28031442
  7. [7]Milovanovic M Nilsson E Järemo P Relationships between platelets and inflammatory markers in rheumatoid arthritis Clin Chim Acta 2004 343 237 240 15115702
  8. [8]Zha Q He Y Lu Y Lu A Relationship between platelet counts and cartilage erosion in 436 cases of rheumatoid arthritis Clin Chim Acta 2006 371 194 195 16626675
  9. [9]Matsuno H Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts Mod Rheumatol 2015 25 38 42 25529071
  10. [10]Üsküdar Cansu D Üsküdar Teke H Musmul A Korkmaz C Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus Rheumatol Int 2018 38 239 247 29119304
  11. [11]Li J Pan Z Liu H Ding F Shu Q Li X Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus Medicine (Baltimore) 2018 97 e11356 29979417 PMC6076144
  12. [12]El-Dairi MA Chang L Proia AD Cummings TJ Stinnett SS Bhatti MT Diagnostic algorithm for patients with suspected giant cell arteritis J Neuroophthalmol 2015 35 246 253 25802967
  13. [13]Bornstein G Barshack I Koren-Morag N Ben-Zvi I Furie N Grossman C Negative temporal artery biopsy: predictive factors for giant cell arteritis diagnosis and alternate diagnoses of patients without arteritis Clin Rheumatol 2018 37 2819 2824 29549493
  14. [14]Han JW Oh JH Rhim JW Lee KY Correlation between elevated platelet count and immunoglobulin levels in the early convalescent stage of Kawasaki disease Medicine (Baltimore) 2017 96 e7583 28723797 PMC5521937
  15. [15]Maric LS Knezovic I Papic N Mise B Roglic S Markovinovic L Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience Rheumatol Int 2015 35 1053 1058 25429794
  16. [16]Elmas AT Platelet counts in children with Henoch-Schonlein purpura—relationship to renal involvement J Clin Lab Anal 2016 30 71 74 25385472 PMC6806727
  17. [17]Cognasse F Hamzeh-Cognasse H Lafarge S Chavarin P Cogné M Richard Y Human platelets can activate peripheral blood B cells and increase production of immunoglobulins Exp Hematol 2007 35 1376 1387 17656005
  18. [18]Koupenova M Clancy L Corkrey HA Freedman JE Circulating platelets as mediators of immunity, inflammation, and thrombosis Circ Res 2018 122 337 351 29348254 PMC5777300
  19. [19]Yeung J Li W Holinstat M Platelet signaling and disease: targeted therapy for thrombosis and other related diseases Pharmacol Rev 2018 70 526 548 29925522 PMC6013590
  20. [20]Olumuyiwa-Akeredolu OO Pretorius E Platelet and red blood cell interactions and their role in rheumatoid arthritis Rheumatol Int 2015 35 1955 1964 26059943
  21. [21]Łukasik ZM Makowski M Makowska JS From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders Rheumatol Int 2018 38 959 974 29492586 PMC5954012
  22. [22]Zamora C Cantó E Nieto JC Bardina J Diaz-Torné C Moya P Binding of platelets to lymphocytes: a potential anti-inflammatory therapy in rheumatoid arthritis J Immunol 2017 198 3099 3108 28250158
  23. [23]Hally KE La Flamme AC Harding SA Larsen PD Platelets regulate leucocyte responses to Toll-like receptor stimulation Clin Transl Immunology 2018 7 e1036 30065836 PMC6063753
  24. [24]Duchez AC Boudreau LH Naika GS Bollinger J Belleannée C Cloutier N Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA Proc Natl Acad Sci U S A 2015 112 E3564 E3573 26106157 PMC4500271
  25. [25]Bunescu A Seideman P Lenkei R Levin K Egberg N Enhanced Fcgamma receptor I. alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets J Rheumatol 2004 31 2347 2355 15570633
  26. [26]Manfredi AA Baldini M Camera M Baldissera E Brambilla M Peretti G Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis Ann Rheum Dis 2016 75 1511 1520 26819099
  27. [27]Kornerup KN Salmon GP Pitchford SC Liu WL Page CP Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration J Appl Physiol (1985) 2010 109 758 767 20558756
  28. [28]Maugeri N Rovere-Querini P Evangelista V Godino C Demetrio M Baldini M An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes PLoS One 2012 7 e39484 22761804 PMC3382567
  29. [29]Habets KL Trouw LA Levarht EW Korporaal SJ Habets PA de Groot P Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis Arthritis Res Ther 2015 17 209 26268317 PMC4548712
  30. [30]Lam FW Da Q Guillory B Cruz MA Recombinant human vimentin binds to p-selectin and blocks neutrophil capture and rolling on platelets and endothelium J Immunol 2018 200 1718 1726 29335256 PMC5821592
  31. [31]Cheng Q Hoi A Hickey MJ Morand EF Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement Lupus 2012 21 632 641 22345121
  32. [32]Roxburgh CS McMillan DC Role of systemic inflammatory response in predicting survival in patients with primary operable cancer Future Oncol 2010 6 149 163 20021215
  33. [33]Gary T Pichler M Belaj K Hafner F Gerger A Froehlich H Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients PLoS One 2013 8 e67888 23844064 PMC3699634
  34. [34]Templeton AJ Ace O McNamara MG Al-Mubarak M Vera-Badillo FE Hermanns T Prognostic role of platelet: lymphocyte ratio in solid tumors: a systematic review and meta-analysis Cancer Epidemiol Biomarkers Prev 2014 23 1204 1212 24793958
  35. [35]Tan D Fu Y Su Q Wang H Prognostic role of platelet: lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis Medicine (Baltimore) 2016 95 e3837 27310960 PMC4998446
  36. [36]Li W Liu Q Tang Y Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis Sci Rep 2017 7 40426 28071752 PMC5223131
  37. [37]Wang Q Ma J Jiang Z Ming L Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis Int Angiol 2018 37 4 11 28541022
  38. [38]Mischler K Fischer JE Zgraggen L Kudielka BM Preckel D von Känel R The effect of repeated acute mental stress on habituation and recovery responses in hemoconcentration and blood cells in healthy men Life Sci 2005 77 1166 1179 15978266
  39. [39]Aktar F Tekin R Mean platelet volume, neutrophil to lymphocyte ratio and platelet: lymphocyte ratio in determining the diagnosis or outcome in children with snakebite Arch Argent Pediatr 2017 115 576 580 29087117
  40. [40]Kilincalp S Çoban Ş Akinci H Hamamcı M Karaahmet F Coşkun Y Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma Eur J Cancer Prev 2015 24 328 333 25304028
  41. [41]Ozawa T Ishihara S Nishikawa T Tanaka T Tanaka J Kiyomatsu T The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer Int J Colorectal Dis 2015 30 1165 1171 26049902
  42. [42]Kwon HC Kim SH Oh SY Lee S Lee JH Choi HJ Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer Biomarkers 2012 17 216 222 22424597
  43. [43]Kim JH Lee JY Kim HK Lee JW Jung SG Jung K Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer World J Gastroenterol 2017 23 505 515 28210087 PMC5291856
  44. [44]You J Zhang H Shen Y Chen C Liu W Zheng M Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients Onco Targets Ther 2017 10 2199 2208 28458563 PMC5403005
  45. [45]Akboga MK Canpolat U Yayla C Ozcan F Ozeke O Topaloglu S Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease Angiology 2016 67 89 95 25922197
  46. [46]Akboga MK Canpolat U Yuksel M Yayla C Yilmaz S Turak O Platelet to lymphocyte ratio as a novel indicator of inflammation is correlated with the severity of metabolic syndrome: a single center large-scale study Platelets 2016 27 178 183 26196312
  47. [48]Akboga YE Bektas H Anlar O Usefulness of platelet to lymphocyte and neutrophil to lymphocyte ratios in predicting the presence of cerebral venous sinus thrombosis and in-hospital major adverse cerebral events J Neurol Sci 2017 380 226 229 28870575
  48. [49]Artoni A Abbattista M Bucciarelli P Gianniello F Scalambrino E Pappalardo E Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis Clin Appl Thromb Hemost 2018 24 808 814 29088921 PMC6714878
  49. [50]Yang W Liu Y Platelet-lymphocyte ratio is a predictor of venous thromboembolism in cancer patients Thromb Res 2015 136 212 215 25533129
  50. [51]Tham T Rahman L Persaud C Olson C Costantino P Venous thromboembolism risk in head and neck cancer: significance of the preoperative platelet-to-lymphocyte ratio Otolaryngol Head Neck Surg 2018 159 85 91 29406795
  51. [52]Koseoglu SB Bone loss and platelet-to-lymphocyte ratio Biomark Med 2017 11 5 10 27917655
  52. [53]Gasparyan AY Ayvazyan L Blackmore H Kitas GD Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors Rheumatol Int 2011 31 1409 1417 21800117
  53. [54]Peng YF Cao L Zeng YH Zhang ZX Chen D Zhang Q Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in patients with rheumatoid arthritis Open Med (Wars) 2015 10 249 253 28352702 PMC5152974
  54. [55]Fu H Qin B Hu Z Ma N Yang M Wei T Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis Clin Lab 2015 61 269 273 25974992
  55. [56]Uslu AU Küçük A Şahin A Ugan Y Yılmaz R Güngör T Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio Int J Rheum Dis 2015 18 731 735 25900081
  56. [58]Wu Y Chen Y Yang X Chen L Yang Y Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus Int Immunopharmacol 2016 36 94 99 27111516
  57. [59]Qin B Ma N Tang Q Wei T Yang M Fu H Neutrophil to lymphocyte ratio (NLR) and platelet: lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients Mod Rheumatol 2016 26 372 376 26403379
  58. [60]Kim HA Jung JY Suh CH Usefulness of neutrophil-to-lymphocyte ratio as a biomarker for diagnosing infections in patients with systemic lupus erythematosus Clin Rheumatol 2017 36 2479 2485 28840341
  59. [61]Huang Y Deng W Zheng S Feng F Huang Z Huang Q Relationship between monocytes to lymphocytes ratio and axial spondyloarthritis Int Immunopharmacol 2018 57 43 46 29471252
  60. [62]Bozan N Alpaycı M Aslan M Cankaya H Kıroglu AF Turan M Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds Eur Arch Otorhinolaryngol 2016 273 3663 3672 27034281
  61. [63]Seng JJB Kwan YH Low LL Thumboo J Fong WSW Role of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and mean platelet volume (MPV) in assessing disease control in Asian patients with axial spondyloarthritis Biomarkers 2018 23 335 338 29307233
  62. [64]Kim DS Shin D Lee MS Kim HJ Kim DY Kim SM Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis J Dermatol 2016 43 305 310 26381893
  63. [65]Alan S Tuna S Türkoğlu EB The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behçet's syndrome Kaohsiung J Med Sci 2015 31 626 631 26709224 PMC11916011
  64. [66]Jiang Y Zang M Li S Serum PLR and LMR in Behçet's disease: can they show the disease activity? Medicine (Baltimore) 2017 96 e6981 28538403 PMC5457883
  65. [67]Avci A Avci D Erden F Ragip E Cetinkaya A Ozyurt K Can we use the neutrophil: lymphocyte ratio, platelet: lymphocyte ratio, and mean platelet volume values for the diagnosis of anterior uveitis in patients with Behcet's disease? Ther Clin Risk Manag 2017 13 881 886 28769565 PMC5529084
  66. [68]La Regina M Gasparyan AY Orlandini F Prisco D Behçet's disease as a model of venous thrombosis Open Cardiovasc Med J 2010 4 71 77 20360979 PMC2847254
  67. [69]Cocco G Gasparyan AY Behçet's disease: an insight from a cardiologist's point of view Open Cardiovasc Med J 2010 4 63 70 20360978 PMC2847211
  68. [70]Balkarli A Kucuk A Babur H Erbasan F Neutrophil/lymphocyte ratio and mean platelet volume in Behçet's disease Eur Rev Med Pharmacol Sci 2016 20 3045 3050 27460734
  69. [71]Oh LJ Wong E Andrici J McCluskey P Smith JEH Gill AJ Full blood count as an ancillary test to support the diagnosis of giant cell arteritis Intern Med J 2018 48 408 413 29236347
  70. [72]Walvick MD Walvick MP Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy Ophthalmology 2011 118 1201 1204 21232803
  71. [73]Pan L Du J Li T Liao H Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu's arteritis: a case-control study BMJ Open 2017 7 e014451 PMC5623399 28473512
  72. [74]Park HJ Jung SM Song JJ Park YB Lee SW Platelet to lymphocyte ratio is associated with the current activity of ANCA-associated vasculitis at diagnosis: a retrospective monocentric study Rheumatol Int 2018 38 1865 1871 30088046
  73. [75]Shin J Lee H Eun L Verification of current risk scores for Kawasaki disease in Korean children J Korean Med Sci 2017 32 1991 1996 29115081 PMC5680498
  74. [76]Ha KS Jang GY Lee J Lee KC Son CS Laboratory markers in incomplete Kawasaki disease according to coronary artery outcome Korean Circ J 2018 48 287 295 29625511 PMC5889978
  75. [77]Kawamura Y Takeshita S Kanai T Yoshida Y Nonoyama S The combined usefulness of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in predicting intravenous immunoglobulin resistance with Kawasaki disease J Pediatr 2016 178 281.e1 284.e1 27526622
  76. [78]Takeshita S Kanai T Kawamura Y Yoshida Y Nonoyama S A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease PLoS One 2017 12 e0176957 28542183 PMC5441585
  77. [79]Yuan YD Sun J Li PF Wei CL Yu YH Values of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in predicting sensitivity to intravenous immunoglobulin in Kawasaki disease Zhongguo Dang Dai Er Ke Za Zhi 2017 19 410 413 28407827 PMC7389660
  78. [80]Chantasiriwan N Silvilairat S Makonkawkeyoon K Pongprot Y Sittiwangkul R Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease Paediatr Int Child Health 2018 38 209 212 29768976
  79. [81]Özer S Yılmaz R Sönmezgöz E Karaaslan E Taşkın S Bütün İ Simple markers for subclinical inflammation in patients with familial Mediterranean fever Med Sci Monit 2015 21 298 303 25615955 PMC4315639
  80. [82]Kelesoglu FM Aygun E Okumus NK Ersoy A Karapınar E Saglam N Evaluation of subclinical inflammation in familial Mediterranean fever patients: relations with mutation types and attack status: a retrospective study Clin Rheumatol 2016 35 2757 2763 27106545
  81. [83]Ozçakar ZB Yalçınkaya F Vascular comorbidities in familial Mediterranean fever Rheumatol Int 2011 31 1275 1281 21437693
  82. [84]Tatsi C Boden R Sinaii N Keil M Lyssikatos C Belyavskaya E Decreased lymphocytes and increased risk for infection are common in endogenous pediatric Cushing syndrome Pediatr Res 2018 83 431 437 29211058 PMC5866174
  83. [85]Bromberg L Roufosse F Pradier O Delporte C Van Antwerpen P De Maertelaer V Methylprednisolone-induced lymphocytosis in patients with immune-mediated inflammatory disorders Am J Med 2016 129 746 752 26968468
  84. [86]Song T Kim MK Kim ML Jung YW Yun BS Seong SJ Single-dose versus two-dose administration of methotrexate for the treatment of ectopic pregnancy: a randomized controlled trial Hum Reprod 2016 31 332 338 26701971
  85. [87]Harigai M Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective Mod Rheumatol 2018 28 1 8 28758827
  86. [88]Inui Y Matsuoka H Yakushijin K Okamura A Shimada T Yano S Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal Leuk Lymphoma 2015 56 3045 3051 25721751
  87. [89]Takanashi S Aisa Y Ito C Arakaki H Osada Y Amano Y Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression Rheumatol Int 2017 37 1629 1633 28676912
  88. [90]Sargin G Senturk T Yavasoglu I Kose R Relationship between neutrophil-lymphocyte, platelet: lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab Int J Rheum Dis 2018 21 2122 2127 30338636
  89. [91]Asahina A Kubo N Umezawa Y Honda H Yanaba K Nakagawa H Neutrophil-lymphocyte ratio, platelet: lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: response to therapy with biologics J Dermatol 2017 44 1112 1121 28493493
  90. [92]Gasparyan AY Ayvazyan L Mikhailidis DP Kitas GD Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011 17 47 58 21247392
  91. [93]Uslu AU Inal S Balta S Assessment of platelet-lymphocyte ratio based on EDTA-dependent pseudothrombocytopenia Angiology 2016 67 96 97 26124494
  92. [94]Ohashi-Fukuda N Inokuchi R Sato H Nakamura K Iwagami M Wada T Poorer prognosis with ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia: a single-center case-control study Medicine (Baltimore) 2015 94 e674 25881844 PMC4602516
  93. [95]Kweon OJ Lee MK Kim HJ Chung JW Choi SH Kim HR Neutropenia and neutrophil: lymphocyte ratio in a healthy Korean population: race and sex should be considered Int J Lab Hematol 2016 38 308 318 27018397
  94. [96]Lee JS Kim NY Na SH Youn YH Shin CS Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea Medicine (Baltimore) 2018 97 e11138 29952958 PMC6039688
  95. [97]Nah EH Kim S Cho S Cho HI Complete blood count reference intervals and patterns of changes across pediatric, adult, and geriatric ages in Korea Ann Lab Med 2018 38 503 511 30027692 PMC6056383
  96. [98]Crawford VL McNerlan SE Stout RW Seasonal changes in platelets, fibrinogen and factor VII in elderly people Age Ageing 2003 32 661 665 14600009
  97. [99]Noris P Melazzini F Balduini CL New roles for mean platelet volume measurement in the clinical practice? Platelets 2016 27 607 612 27686008
  98. [100]Kocak MZ Aktas G Erkus E Duman TT Atak BM Savli H Mean platelet volume to lymphocyte ratio as a novel marker for diabetic nephropathy J Coll Physicians Surg Pak 2018 28 844 847 30369376
  99. [101]Gogoi P Sinha P Gupta B Firmal P Rajaram S Neutrophil-to-lymphocyte ratio and platelet indices in pre-eclampsia Int J Gynaecol Obstet 2019 144 16 20 30362112
  100. [102]Sağ S Sağ MS Tekeoğlu I Kamanlı A Nas K Acar BA Relationship of hematologic markers with IL-17 and IL-1 beta in patients with rheumatoid arthritis J Back Musculoskelet Rehabil 2018 31 703 707 29578474
  101. [103]Tekeoğlu İ Gürol G Harman H Karakeçe E Çiftçi İH Overlooked hematological markers of disease activity in rheumatoid arthritis Int J Rheum Dis 2016 19 1078 1082 26620362
  102. [104]Xie S Chen X Red blood cell distribution width-to-platelet ratio as a disease activity-associated factor in systemic lupus erythematosus Medicine (Baltimore) 2018 97 e12342 30278511 PMC6181617

Cited by

Sorted by citations

Items 401–500 of 553

Metadata

Authors
Gasparyan, A. Y., Ayvazyan, L., Mukanova, U., Yessirkepov, M., & Kitas, G. D.
Affiliations
  • Russells Hall Hospital (GB)
  • Yerevan State Medical University (AM)
  • South Kazakhstan Medical Academy (KZ)
Corresponding author
Gasparyan, Armen Yuri
ORCID
Venue
Annals of Laboratory Medicine
Publisher
Annals of Laboratory Medicine
Published
2019-07-01
Volume
39
Issue
4
Pages
345-357
ISSN
  • 2234-3806 (ISSN-L)
  • 2234-3814
DOI
10.3343/alm.2019.39.4.345
PMC
PMC6400713
OpenAlex
W2917958408
Cited by
607
References
106
Citations by year
2026: 69 · 2025: 101 · 2024: 105 · 2023: 95 · 2022: 95 · 2021: 79 · 2020: 47 · 2019: 13
FWCI
5.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Laboratory Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
platelet-to-lymphocyte ratio, inflammatory markers, rheumatic diseases, systemic lupus erythematosus, neutrophil-to-lymphocyte ratio, Behçet's disease, familial Mediterranean fever, giant cell arteritis, vasculitis, neutrophilic inflammation, systemic inflammation, infection prediction
MeSH terms
Anti-Inflammatory Agents, Blood Platelets, Humans, Lymphocytes, Neoplasms, Rheumatic Diseases, Giant Cell Arteritis, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review